SLC5A2 and chronic kidney disease: Specifically, clinical trials including DAPA-HF, EMPEROR, CREDENCE, DAPA-CKD, and EMPA-KIDNEY have established SGLT2 inhibitors protective effects as evidenced by the reduction of worsening heart failure and progression to kidney failure in patients with heart failure and/or chronic kidney disease (CKD).